ClinicalTrials.gg
RecruitingNCT05729009Updated Apr 13, 2026

The Evolution of Systemic Microvascular Reactivity in Heart Transplant Patients

An observational study in Heart Transplantation, sponsored by National Institute of Cardiology, Laranjeiras, Brazil. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by National Institute of Cardiology, Laranjeiras, Brazil · Observational

How we know

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
31
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The evolution of systemic microvascular reactivity may aid in the comprehension of cardiovascular physiology in heart transplantation patients, and possibly suggest the non-invasive evaluation of skin microcirculation as an ancillary tool in the clinical evaluation of these patients.

Read the detailed description

Introduction: Systemic microvascular reactivity (MR) is an essential component of cardiovascular physiology, being studied through non-invasive techniques in readily accessible body regions, such as the skin surface. Heart transplant (HT) is a treatment considered to selected patients, with advanced heart failure. The main cause of long-term mortality after HT is graft vascular disease (GVD), a condition which starts with endothelial dysfunction. To know the evolution of systemic MR in patients subjected to HT can help to find prognostic factors. Objective: The present study aims to perform the prospective evaluation of systemic MR in adult patients, before and two years after HT, at a quaternary hospital, correlating the findings with clinical variables. Methods: Systemic MR will be evaluated in the skin of the forearm using laser speckle contrast imaging with acetylcholine (ACh) iontophoresis, followed by postocclusive reactive hyperemia (PORH), before and after HT. Measurements will be correlated to patient clinical profile, hemodynamic and echocardiographic data. Expected results: The evolution of systemic MR may aid in the comprehension of cardiovascular physiology in HT patients, and possibly suggest the non-invasive evaluation of skin microcirculation as an ancillary tool in the clinical evaluation of these patients.

02

Conditions studied

  • Heart Transplantation
03

In context

Lead sponsor

National Institute of Cardiology, Laranjeiras, Brazil is the lead sponsor of 21 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

adult individuals from the cohort of heart failure patients under evaluation for heart transplantation, at the National Institute of Cardiology, Rio de Janeiro, Brazil

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • capability to understand the objectives of the research and to fulfill the Term of Consent

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, acute infection diagnosis, use of circulatory assistance devices
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
31 participants (estimated)
Patient registry
No

Groups and cohorts

  • heart transplantation

    Diagnostic Test: skin microvascular reactivity

Interventions

  • Diagnostic testskin microvascular reactivity

    Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.

06

What researchers measure

Primary outcomes

  1. Baseline and post-iontophoresis of acetylcholine endothelium-dependent skin microvascular reactivity

    Evaluation of systemic microvascular reactivity induced by endothelium-dependent agents. Microvascular reactivity will be evaluated using a non-invasive and operator -independent methodology, named laser speckle contrast imaging, coupled with skin iontophoresis of vasodilator agents. Cutaneous microvascular flow will be measured in arbitrary perfusion units, divided by mean arterial pressure, to yield cutaneous vascular conductance.

    Time frame: Microvascular reactivity will be evaluated 20-minute rest in the supine position in a temperature-controlled room.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2022 (actual). Primary completion is estimated for Dec 2026, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2023
First posted
Feb 15, 2023
StartActual
Oct 1, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05729009
Lead sponsor
National Institute of Cardiology, Laranjeiras, Brazil
Responsible party
Eduardo Tibirica, MD, PhD (Principal Investigator, National Institute of Cardiology, Laranjeiras, Brazil) — Principal investigator
First posted
Feb 15, 2023
Start date
Oct 1, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 13, 2026

Study contacts

Eduardo Tibirica Tibirica, MD, PhD
Contact
etibi@uol.com.br
+55-21-99914-6075

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion